---
layout: post
title: 'SMR Award Meeting: Recent Disclosures of Clinical Candidates - December 10th,
  London.'
date: '2009-10-25T20:44:00.001Z'
author: John Overington
tags:
- Conferences
modified_time: '2009-10-25T20:45:14.146Z'
thumbnail: http://1.bp.blogspot.com/_SlPG9DIz_AA/SuS4PwEzozI/AAAAAAAAAjc/S5eYU3qM9nQ/s72-c/AtAtATurner.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-3857527220361350482
blogger_orig_url: http://chembl.blogspot.com/2009/10/smr-award-meeting-recent-disclosures-of.html
---

<div class="separator" style="clear: both; text-align: center;"><a href="http://1.bp.blogspot.com/_SlPG9DIz_AA/SuS4PwEzozI/AAAAAAAAAjc/S5eYU3qM9nQ/s1600-h/AtAtATurner.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="238" src="http://1.bp.blogspot.com/_SlPG9DIz_AA/SuS4PwEzozI/AAAAAAAAAjc/S5eYU3qM9nQ/s320/AtAtATurner.jpg" width="320" /></a><br />
</div><p>There is, what looks like, an excellent meeting in London, full details are on the <a href="http://www.smr.org.uk/">SMR website</a>. I hope I feel better by then.<br />
<br />
<table border="0" cellpadding="0" cellspacing="0" height="688"><tbody>
<tr><td colspan="2" height="24" width="100%"><br />
</td></tr>
<tr><td colspan="2" height="110" valign="top" width="100%"><div align="center"><b><span style="font-family: Tahoma; font-size: large;">SMR Award Meeting: Recent Disclosures of Clinical Candidates</span></b><br />
</div><div align="center" dir="ltr"><span style="font-family: Tahoma; font-size: 11pt;">10th December 2009<br />
&nbsp;</span><span style="font-family: Tahoma; font-size: small;">National Heart &amp; Lung Institute, Kensington, London</span><br />
</div></td></tr>
<tr><td colspan="2" height="20" width="100%"><span style="font-family: Tahoma;"><b><span style="font-size: 11pt;">Programme</span></b></span><span style="font-family: Tahoma; font-size: 11pt;"><b>:</b></span><br />
</td></tr>
<tr><td colspan="2" height="21" width="100%"><br />
</td></tr>
<tr><td height="18" valign="top"><b><span style="color: #008070; font-family: Tahoma; font-size: x-small;">09.30</span></b><br />
</td><td height="18" valign="top"><b><i><span style="color: #008070; font-family: Tahoma; font-size: x-small;">Registration and coffee</span></i></b><br />
</td></tr>
<tr><td height="10" valign="top"></td><td height="10" valign="top"></td></tr>
<tr><td height="10" valign="top"><b><span style="font-family: Tahoma; font-size: x-small;">10.0</span></b><span style="font-family: Tahoma; font-size: x-small;"><b>0</b></span><br />
</td><td height="10" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>SMR Award lecture: The Discovery and development of Januvia</b></span><span style="font-size: medium;">â„¢</span><span style="font-family: Tahoma; font-size: x-small;"><b>,<span style="color: #008070;">&nbsp;</span></b></span><b><span style="color: #008070; font-family: Tahoma; font-size: x-small;">Dr. Ann Weber</span></b><span style="font-family: Tahoma; font-size: x-small;"><span style="color: #008070;"><b>,</b>&nbsp;Merck</span><b><br />
(Introduction by -&nbsp;<span style="color: #008070;">Rob Williams,&nbsp;</span></b><span style="color: #008070;">Cancer Research UK</span><b>)</b></span><br />
</td></tr>
<tr><td height="10" valign="top"></td><td height="10" valign="top"></td></tr>
<tr><td colspan="2" height="18" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>Session 1 - Chair: Mark Searcy,&nbsp;</b>University of East Anglia</span><br />
</td></tr>
<tr><td height="10" valign="top"></td><td height="10"></td></tr>
<tr><td height="36" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>11.00&nbsp; &nbsp;</b></span><br />
</td><td height="36" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>Chris Murray,&nbsp;</b>Astex<br />
</span><b><i><span style="color: grey; font-family: Tahoma; font-size: x-small;">From fragment to clinic - the discovery of the hsp90 inhibitor, AT13387.</span></i></b><br />
</td></tr>
<tr><td height="36" valign="top"><b><span style="font-family: Tahoma; font-size: x-small;">11.45</span></b><br />
</td><td height="36" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>George Muller,&nbsp;</b>Celgene<br />
</span><b><i><span style="color: grey; font-family: Tahoma; font-size: x-small;">The discovery of apremilast.</span></i></b><br />
</td></tr>
<tr><td height="10" valign="top"></td><td height="10" valign="top"></td></tr>
<tr><td height="18" valign="top"><b><span style="color: #008070; font-family: Tahoma; font-size: x-small;">12.30</span></b><br />
</td><td height="18" valign="top"><b><span style="color: #008070; font-family: Tahoma; font-size: x-small;">Lunch (Including SMR AGM 13.10-13.30)</span></b><br />
</td></tr>
<tr><td height="10" valign="top"></td><td height="10" valign="top"></td></tr>
<tr><td colspan="2" height="18" valign="top"><div dir="ltr"><span style="font-family: Tahoma; font-size: x-small;"><b>Session 2 - Chair:&nbsp;</b></span><span style="font-family: Tahoma; font-size: x-small;"><b>Diane Coe,&nbsp;</b>GSK</span><br />
</div></td></tr>
<tr><td height="36" valign="top"><b><span style="font-family: Tahoma; font-size: x-small;">13.30</span></b><br />
</td><td height="36" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>David Fox,</b>&nbsp;Pfizer<br />
<i><span style="color: grey;"><b>The discovery of a second generation long-acting PDE5 inhibitor.</b></span></i></span><br />
</td></tr>
<tr><td height="10" valign="top"></td><td height="10" valign="top"></td></tr>
<tr><td height="36" valign="top"><b><span style="font-family: Tahoma; font-size: x-small;">14.15</span></b><br />
</td><td height="36" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>Simon Hodgson,&nbsp;</b>GSK<br />
<span style="color: grey;"><b><i>T</i></b></span><i><span style="color: grey;"><b>he discovery of a dual H1/H3 antagonist for allergic rhinitis.</b></span></i></span><br />
</td></tr>
<tr><td height="9" valign="top"></td><td height="9" valign="top"></td></tr>
<tr><td height="17" valign="top"><b><span style="color: #008070; font-family: Tahoma; font-size: x-small;">15.00</span></b><br />
</td><td height="17" valign="top"><b><span style="color: #008070; font-family: Tahoma; font-size: x-small;">Tea</span></b><br />
</td></tr>
<tr><td height="9" valign="top"></td><td height="9" valign="top"></td></tr>
<tr><td colspan="2" height="17" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>Session 3 - Chair: David Fox,&nbsp;</b>Pfizer</span><br />
</td></tr>
<tr><td height="35" valign="top"><b><span style="font-family: Tahoma; font-size: x-small;">15.30</span></b><br />
</td><td height="35" valign="top"><div dir="ltr"><span style="font-family: Tahoma; font-size: x-small;"><b>Karl Gibson,</b>&nbsp;Pfizer<br />
</span><b><i><span style="color: grey; font-family: Tahoma; font-size: x-small;">The discovery of a progesterone receptor antagonist for endometriosis.</span></i></b><br />
</div></td></tr>
<tr><td height="35" valign="top"><b><span style="font-family: Tahoma; font-size: x-small;">16.15</span></b><br />
</td><td height="35" valign="top"><span style="font-family: Tahoma; font-size: x-small;"><b>Mairi Gibson,&nbsp;</b>GSK<br />
</span><b><i><span style="color: grey; font-family: Tahoma; font-size: x-small;">Second generation EP1 antagonists for the treatment of pain.</span></i></b><br />
</td></tr>
<tr><td height="9" valign="top"></td><td height="9" valign="top"></td></tr>
<tr><td height="17" valign="top"><b><span style="color: #008070; font-family: Tahoma; font-size: x-small;">17.00</span></b><br />
</td><td height="17" valign="top"><b><span style="color: #008070; font-family: Tahoma; font-size: x-small;">Close</span></b><br />
</td></tr>
</tbody></table>